Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy.

IF 4.1 Q2 IMMUNOLOGY

Immunotherapy advances Pub Date : 2022-01-01 DOI:10.1093/immadv/ltac003

Dayane Schmidt, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, Graziela de Moura Aguiar, Mariane Cariati Tirapelle, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Dimas Tadeu Covas, Virginia Picanço-Castro

{"title":"Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy.","authors":"Dayane Schmidt, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, Graziela de Moura Aguiar, Mariane Cariati Tirapelle, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Dimas Tadeu Covas, Virginia Picanço-Castro","doi":"10.1093/immadv/ltac003","DOIUrl":null,"url":null,"abstract":"<p><p>Cell therapy is an innovative approach that permits numerous possibilities in the field of cancer treatment. CAR-T cells have been successfully used in patients with hematologic relapsed/refractory. However, the need for autologous sources for T cells is still a major drawback. CAR-NK cells have emerged as a promising resource using allogeneic cells that could be established as an off-the-shelf treatment. NK cells can be obtained from various sources, such as peripheral blood (PB), bone marrow, umbilical cord blood (CB), and induced pluripotent stem cells (iPSC), as well as cell lines. Genetic engineering of NK cells to express different CAR constructs for hematological cancers and solid tumors has shown promising preclinical results and they are currently being explored in multiple clinical trials. Several strategies have been employed to improve CAR-NK-cell expansion and cytotoxicity efficiency. In this article, we review the latest achievements and progress made in the field of CAR-NK-cell therapy.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"2 1","pages":"ltac003"},"PeriodicalIF":4.1000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327111/pdf/","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/immadv/ltac003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 6

Abstract

Cell therapy is an innovative approach that permits numerous possibilities in the field of cancer treatment. CAR-T cells have been successfully used in patients with hematologic relapsed/refractory. However, the need for autologous sources for T cells is still a major drawback. CAR-NK cells have emerged as a promising resource using allogeneic cells that could be established as an off-the-shelf treatment. NK cells can be obtained from various sources, such as peripheral blood (PB), bone marrow, umbilical cord blood (CB), and induced pluripotent stem cells (iPSC), as well as cell lines. Genetic engineering of NK cells to express different CAR constructs for hematological cancers and solid tumors has shown promising preclinical results and they are currently being explored in multiple clinical trials. Several strategies have been employed to improve CAR-NK-cell expansion and cytotoxicity efficiency. In this article, we review the latest achievements and progress made in the field of CAR-NK-cell therapy.

Abstract Image

查看原文本刊更多论文

工程CAR-NK细胞:如何调整癌症免疫治疗的先天杀伤细胞。

细胞疗法是一种创新的方法，在癌症治疗领域提供了许多可能性。CAR-T细胞已成功用于血液病复发/难治性患者。然而，需要T细胞的自体来源仍然是一个主要的缺点。CAR-NK细胞已经成为一种很有前途的资源，使用同种异体细胞可以建立一种现成的治疗方法。NK细胞可以从多种来源获得，如外周血(PB)、骨髓、脐带血(CB)、诱导多能干细胞(iPSC)以及细胞系。NK细胞的基因工程表达不同的CAR结构用于血液病和实体瘤已经显示出有希望的临床前结果，目前正在多个临床试验中进行探索。已经采用了几种策略来提高car - nk细胞的扩增和细胞毒性效率。本文就car - nk细胞治疗领域的最新成果和进展进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊